Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy

• DOI: 10.1111/bju.12522
• Publication Date: 2013-10-21T12:24:41Z
• Authors: Jennifer L. Beebe...; William B. Isaacs; Kimberly A. Zuhlke; Cecilia Yee; Patrick C. Walsh; Sarah D. Isaacs; Anna M. Johnson; Charles E. Ewing; Elizabeth B. Hump...; Wasim H. Chowdhury; James E. Montie; Kathleen A. Cooney
• Keywords: Adult; Male; Genotype; DNA Mutational Analysis; 03 medical and health sciences; 0302 clinical medicine; Risk Factors; Health Sciences; Biomarkers, Tumor; Prevalence; Humans; Genetic Predisposition to Disease; Family History; Alleles; Aged; Retrospective Studies; Homeodomain Proteins; Prostatectomy; Prostate Cancer; Prostatic Neoplasms; HOXB13; DNA; Middle Aged; United States; 3. Good health; Genetic Epidemiology; Internal Medicine and Specialties; Mutation; Follow-Up Studies

Objective To determine the prevalence and clinical correlates of the G84E mutation in the homeobox transcription factor, or HOXB13, gene using DNA samples from 9559 men with prostate cancer undergoing radical prostatectomy. Patients and Methods DNA samples from men treated with radical prostatectomy at the University of Michigan and John Hopkins University were genotyped for G84E and this was confirmed by Sanger sequencing. The frequency and distribution of this allele was determined according to specific patient characteristics (family history, age at diagnosis, pathological Gleason grade and stage). Results Of 9559 patients, 128 (1.3%) were heterozygous carriers of G84E. Patients who possessed the variant were more likely to have a family history of prostate cancer than those who did not (46.0 vs 35.4%; P = 0.006). G84E carriers were also more likely to be diagnosed at a younger age than non‐carriers (55.2 years vs 58.1 years; P < 0.001). No difference in the proportion of patients diagnosed with high grade or advanced stage tumours according to carrier status was observed. Conclusions In the present study, carriers of the rare G84E variant in HOXB13 were both younger at the time of diagnosis and more likely to have a family history of prostate cancer compared with homozygotes for the wild‐type allele. No significant differences in allele frequency were detected according to selected clinical characteristics of prostate cancer. Further investigation is required to evaluate the role of HOXB13 in prostate carcinogenesis.